Overview

  • Product nameAnti-Collagen IV antibodySee all Collagen IV primary antibodies ...
  • Description
    Rabbit polyclonal to Collagen IV
  • SpecificityRecognises: Human collagen type IV 100% Human collagen types I, II <0.1% Human collagen type III, V <1.0% Human Fibronectin <0.1% Mouse Laminin <0.1%
  • Tested applicationsIHC-Fr, ICC/IF, ELISA, RIA, IHC-P more details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Full length native protein (purified): Collagen type IV extracted and purified from human placenta

  • Positive control
    • IHC-P: human placenta FFPE tissue sections.

Properties

Applications

Our Abpromise guarantee covers the use of ab21295 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
IHC-Fr Use at an assay dependent dilution. PubMed: 20434214
ICC/IF Use at an assay dependent dilution.
ELISA Use at an assay dependent dilution.
RIA Use at an assay dependent dilution.
IHC-P Use a concentration of 1 µg/ml. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.

Target

  • FunctionType IV collagen is the major structural component of glomerular basement membranes (GBM), forming a 'chicken-wire' meshwork together with laminins, proteoglycans and entactin/nidogen.
    Arresten, comprising the C-terminal NC1 domain, inhibits angiogenesis and tumor formation. The C-terminal half is found to possess the anti-angiogenic activity. Specifically inhibits endothelial cell proliferation, migration and tube formation. Inhibits expression of hypoxia-inducible factor 1alpha and ERK1/2 and p38 MAPK activation. Ligand for alpha1/beta1 integrin.
  • Tissue specificityHighly expressed in placenta.
  • Involvement in diseaseDefects in COL4A1 are a cause of brain small vessel disease with hemorrhage (BSVDH) [MIM:607595]. Brain small vessel diseases underlie 20 to 30 percent of ischemic strokes and a larger proportion of intracerebral hemorrhages. Inheritance is autosomal dominant.
    Defects in COL4A1 are the cause of hereditary angiopathy with nephropathy aneurysms and muscle cramps (HANAC) [MIM:611773]. The clinical renal manifestations include hematuria and bilateral large cysts. Histologic analysis revealed complex basement membrane defects in kidney and skin. The systemic angiopathy appears to affect both small vessels and large arteries.
    Defects in COL4A1 are a cause of porencephaly familial (PCEPH) [MIM:175780]. Porencephaly is a term used for any cavitation or cerebrospinal fluid-filled cyst in the brain. Porencephaly type 1 is usually unilateral and results from focal destructive lesions such as fetal vascular occlusion or birth trauma. Type 2, or schizencephalic porencephaly, is usually symmetric and represents a primary defect or arrest in the development of the cerebral ventricles.
  • Sequence similaritiesBelongs to the type IV collagen family.
    Contains 1 collagen IV NC1 (C-terminal non-collagenous) domain.
  • DomainAlpha chains of type IV collagen have a non-collagenous domain (NC1) at their C-terminus, frequent interruptions of the G-X-Y repeats in the long central triple-helical domain (which may cause flexibility in the triple helix), and a short N-terminal triple-helical 7S domain.
  • Post-translational
    modifications
    Lysines at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in all cases and bind carbohydrates.
    Prolines at the third position of the tripeptide repeating unit (G-X-Y) are hydroxylated in some or all of the chains.
    Type IV collagens contain numerous cysteine residues which are involved in inter- and intramolecular disulfide bonding. 12 of these, located in the NC1 domain, are conserved in all known type IV collagens.
    The trimeric structure of the NC1 domains is stabilized by covalent bonds between Lys and Met residues.
    Proteolytic processing produces the C-terminal NC1 peptide, arresten.
  • Cellular localizationSecreted > extracellular space > extracellular matrix > basement membrane.
  • Target information above from: UniProt accession P02462 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
    • Arresten antibody
    • Canstatin antibody
    • CO4A1_HUMAN antibody
    • COL4A1 antibody
    • COL4A1 NC1 domain antibody
    • COL4A2 antibody
    • COL4A3 antibody
    • COL4A4 antibody
    • COL4A5 antibody
    • Collagen Alpha 1(IV) Chain antibody
    • Collagen Alpha 2(IV) Chain antibody
    • collagen alpha-1(IV) chain antibody
    • Collagen IV Alpha 1 Polypeptide antibody
    • Collagen IV Alpha 2 Polypeptide antibody
    • Collagen Of Basement Membrane Alpha 1 Chain antibody
    • Collagen Of Basement Membrane Alpha 2 Chain antibody
    • Collagen Type IV Alpha 1 antibody
    • Collagen Type IV Alpha 2 antibody
    • Collagen Type IV Alpha 3 antibody
    • Collagen Type IV Alpha 4 antibody
    • Collagen Type IV Alpha 5 antibody
    • DKFZp686I14213 antibody
    • FLJ22259 antibody
    see all

Anti-Collagen IV antibody images

  • IHC image of Collagen IV staining in human placenta formalin fixed paraffin embedded tissue section, performed on a Leica BondTM system using the standard protocol F. The section was pre-treated using heat mediated antigen retrieval with sodium citrate buffer (pH6, epitope retrieval solution 1) for 20 mins. The section was then incubated with ab21295, 1µg/ml, for 15 mins at room temperature and detected using an HRP conjugated compact polymer system. DAB was used as the chromogen. The section was then counterstained with haematoxylin and mounted with DPX.

    For other IHC staining systems (automated and non-automated) customers should optimize variable parameters such as antigen retrieval conditions, primary antibody concentration and antibody incubation times.

References for Anti-Collagen IV antibody (ab21295)

This product has been referenced in:
  • Jean J  et al. Effects of serum-free culture at the air-liquid interface in a human tissue-engineered skin substitute. Tissue Eng Part A 17:877-88 (2011). IHC-Fr ; Human . Read more (PubMed: 21067466) »
  • Rouabhia M & Allaire P Gingival mucosa regeneration in athymic mice using in vitro engineered human oral mucosa. Biomaterials 31:5798-804 (2010). IHC-Fr ; Human . Read more (PubMed: 20434214) »

See all 2 Publications for this product

Product Wall

There are currently no Abreviews or Questions for ab21295.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"